HeartBeam (BEATW) stock price is $0.03, up 31.18% on the day, as of Oct 20, 2026. It has a market cap of $21.64Mn, and is classified in the Medical Devices industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap21.64 Mn
P/E-1.07
P/S196.71
Div. Yield0.00
Revenue Growth (1y) (Qtr)-15.87
Add ratio to table…
About
HeartBeam is a medical technology company focused on transforming cardiac care through the power of personalized insights. The company develops higher resolution ambulatory cardiac monitoring solutions that enable detection and monitoring of cardiac disease outside healthcare facilities. Its core innovation lies in a proprietary patented technology platform that collects the heart’s electrical activity from three dimensions and synthesizes a 12-Lead ECG from these signals.…
HeartBeam is a medical technology company focused on transforming cardiac care through the power of personalized insights. The company develops higher resolution ambulatory cardiac monitoring solutions that enable detection and monitoring of cardiac disease outside healthcare facilities. Its core innovation lies in a proprietary patented technology platform that collects the heart’s electrical activity from three dimensions and synthesizes a 12-Lead ECG from these signals. HeartBeam’s initial product and service offering is the HeartBeam System, which is the first U. S. FDA cleared cable-free ambulatory 12L ECG that captures cardiac signals in three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment. The system includes a credit card sized 3D ECG recording device, a patient application, a physician portal, and cloud-based algorithms.
HeartBeam generates revenue through the sale of its HeartBeam System and associated services. The primary product is the FDA cleared cable-free ambulatory 12L ECG device designed for arrhythmia assessment. Revenue is derived from the sale of the hardware device, patient application access, physician portal usage, and cloud-based algorithm services. The company targets customers seeking convenient cardiac monitoring solutions outside traditional healthcare settings. As of December 31, 2025, HeartBeam had not generated any revenue from the HeartBeam System, as it was focused on post-clearance commercialization activities following FDA clearance in December 2024 for arrhythmia assessment and December 2025 for the 12-Lead ECG synthesis software.
The company operates through the following segments:
HeartBeam System segment. This segment encompasses the development, manufacturing, and commercialization of the HeartBeam System, which includes the credit card sized 3D ECG recording device, patient application, physician portal, and cloud-based algorithms for synthesizing a 12-Lead ECG from three-dimensional cardiac signals. The segment focuses on arrhythmia assessment and is supported by FDA clearances obtained in December 2024 and December 2025. Activities include limited market launch in early 2026 targeting concierge and preventive cardiology groups, pursuit of heart attack detection indication, development of an extended wear patch monitor, and longitudinal data and AI initiatives for future screening and prediction algorithms.
HeartBeam operates in a competitive cardiac monitoring and detection market characterized by rapid technological change. The company faces competition from consumer devices such as Apple Watch, AliveCor’s KardiaMobile, Google Pixel 2, and Samsung Galaxy Watch, which are single-lead ECG devices primarily intended for arrhythmia detection and not ischemia detection. In the prescribed devices for ischemia detection segment, competitors include Avertix Medical’s AngelMed Guardian implantable cardiac monitor and SHL Telemedicine’s Smartheart home-based 12L ECG system. Patch monitoring companies such as iRhythm Technologies, Boston Scientific’s BodyGuardian, and BioTelemetry (a Philips subsidiary) offer single or 3-lead ECG patches limited to arrhythmia detection. HeartBeam differentiates itself through its patented cable-free technology that captures cardiac signals in three non-coplanar dimensions and synthesizes them into a 12-Lead ECG display, offering a portable, easy-to-use solution that provides comprehensive diagnostic data comparable to standard 12L ECG machines. Its competitive advantages include the credit card sized form factor, personalized baseline ECG capability, and integration with on-demand cardiologist review.
HeartBeam serves customers in the cardiac monitoring market, including patients, healthcare providers, and healthcare payers. The company’s primary customers are concierge physicians, preventive cardiology practices, and cardiology departments of hospitals. Healthcare insurers are also an important customer segment due to potential cost savings to the healthcare system. The company targets market segments that value an easy-to-use medical-grade ECG device, including concierge practices, hospital-at-home programs, and clinical trial settings. HeartBeam aims to establish its products as key solutions for these customers through clinical evidence, cost-effectiveness demonstrations, and reference site development.
Sector:HealthcareSector rationaleHeartBeam develops and sells the HeartBeam System, an FDA-cleared medical device for ambulatory 12-lead ECG recording and arrhythmia assessment. Its primary customers are healthcare providers, such as cardiology practices and hospitals, and its revenue model is based on the sale of medical hardware and associated diagnostic services.Industries:Medical DevicesMedical DevicesPrimaryHeartBeam designs and manufactures the HeartBeam System, which is an FDA-cleared cable-free ambulatory 12L ECG recording device used for arrhythmia assessment. This is a therapeutic and surgical medical device used for clinical diagnostics outside of healthcare facilities.Diagnostic EquipmentDiagnostic EquipmentSecondaryThe company sells cloud-based algorithms and a physician portal used to synthesize 12-Lead ECGs from 3D signals for advanced diagnostics. These software components and the associated hardware function as a clinical diagnostic platform for arrhythmia and ischemia detection.Classified using BQ-MICSCIK: 0001779372
Bull & bear
Investment Thesis
▲ Bull case
HeartBeam’s strategic collaboration with the Icahn School of Medicine at Mount Sinai represents a fundamentally underappreciated catalyst that positions the company to dominate the next generation of AI-driven cardiac monitoring. By combining HeartBeam’s unique capability to synthesize longitudinal, high-fidelity 12-lead ECG data from home settings with Mount Sinai’s clinically annotated datasets and AI expertise, the partnership creates a proprietary data engine that could accelerate the development of personalized algorithms far beyond what competitors can achieve using isolated clinical snapshots. This access to real-world, continuous cardiac data—historically inaccessible for AI training—allows HeartBeam to train models that detect subtle, dynamic changes in cardiac health earlier than traditional methods, unlocking opportunities in preventive cardiology and chronic disease management. The collaboration explicitly targets expansion into new clinical indications and reimbursement pathways, which management did not heavily promote but is critical for long-term scalability. Given that the addressable market for AI-enabled cardiac monitoring is projected to grow at a double-digit CAGR, HeartBeam’s early mover advantage in building this data ecosystem could establish formidable barriers to entry and drive sustainable premium valuation multiples as the platform transitions from arrhythmia assessment to broader diagnostic applications.
The company’s recent capital raise of $10 million in gross proceeds, coupled with strategic investor participation from ClearCardio™—its first commercial customer—provides both financial runway and endogenous validation that the market is underestimating. This financing, structured to support commercialization of the FDA-cleared 12-lead synthesized ECG system, extended-wear patch development, heart attack detection initiatives, and AI enhancements, directly addresses the capital intensity typically associated with MedTech scaling. More importantly, ClearCardio’s dual role as both a commercial partner and investor signals strong conviction in HeartBeam’s technology fit within high-engagement preventive cardiology and concierge markets, where patients are willing to pay for proactive, out-of-clinic cardiac insights. This alignment reduces go-to-market risk and accelerates adoption through trusted clinical channels, potentially enabling faster-than-expected revenue recognition from subscription-based models. The proceeds also strengthen the balance sheet, with cash and cash equivalents rising to $4.4 million as of December 2025, providing critical liquidity to execute on near-term milestones without dilutive pressure or reliance on volatile public markets.
HeartBeam’s platform strategy—leveraging its core 3D ECG technology across multiple form factors (credit card-sized device and extended-wear patch)—creates a scalable ecosystem that the market is failing to fully appreciate as a structural shift rather than a temporary product rollout. The ability to synthesize clinical-grade 12-lead ECG signals from a cable-free, home-use device addresses a critical gap in remote cardiac monitoring, particularly for arrhythmia and impending heart attack detection, where current tools are either bulky, clinic-dependent, or lack sufficient diagnostic fidelity. Management’s commentary emphasizes that the technology enables a full range of capabilities including arrhythmia, heart attack detection, and personalized AI algorithms, all of which target large, underserved markets with established reimbursement pathways. The extended-wear patch alone targets the combined $2B long-term continuous monitor and mobile cardiac telemetry (MCT) markets, suggesting that even modest penetration could yield meaningful revenue. This multi-indication, platform-based approach transforms HeartBeam from a single-product vendor into a cardiac intelligence provider with recurring revenue potential, a narrative that remains underpriced in the current valuation.
HeartBeam’s strategic collaboration with the Icahn School of Medicine at Mount Sinai represents a fundamentally underappreciated catalyst that positions the company to dominate the next generation of AI-driven cardiac monitoring. By combining HeartBeam’s unique capability to synthesize longitudinal, high-fidelity 12-lead ECG data from home settings with Mount Sinai’s clinically annotated datasets and AI expertise, the partnership creates a proprietary data engine that could accelerate the development of personalized algorithms far beyond what competitors can achieve using isolated clinical snapshots. This access to real-world, continuous cardiac data—historically inaccessible for AI training—allows HeartBeam to train models that detect subtle, dynamic changes in cardiac health earlier than traditional methods, unlocking opportunities in preventive cardiology and chronic disease management. The collaboration explicitly targets expansion into new clinical indications and reimbursement pathways, which management did not heavily promote but is critical for long-term scalability. Given that the addressable market for AI-enabled cardiac monitoring is projected to grow at a double-digit CAGR, HeartBeam’s early mover advantage in building this data ecosystem could establish formidable barriers to entry and drive sustainable premium valuation multiples as the platform transitions from arrhythmia assessment to broader diagnostic applications.
The company’s recent capital raise of $10 million in gross proceeds, coupled with strategic investor participation from ClearCardio™—its first commercial customer—provides both financial runway and endogenous validation that the market is underestimating. This financing, structured to support commercialization of the FDA-cleared 12-lead synthesized ECG system, extended-wear patch development, heart attack detection initiatives, and AI enhancements, directly addresses the capital intensity typically associated with MedTech scaling. More importantly, ClearCardio’s dual role as both a commercial partner and investor signals strong conviction in HeartBeam’s technology fit within high-engagement preventive cardiology and concierge markets, where patients are willing to pay for proactive, out-of-clinic cardiac insights. This alignment reduces go-to-market risk and accelerates adoption through trusted clinical channels, potentially enabling faster-than-expected revenue recognition from subscription-based models. The proceeds also strengthen the balance sheet, with cash and cash equivalents rising to $4.4 million as of December 2025, providing critical liquidity to execute on near-term milestones without dilutive pressure or reliance on volatile public markets.
HeartBeam’s platform strategy—leveraging its core 3D ECG technology across multiple form factors (credit card-sized device and extended-wear patch)—creates a scalable ecosystem that the market is failing to fully appreciate as a structural shift rather than a temporary product rollout. The ability to synthesize clinical-grade 12-lead ECG signals from a cable-free, home-use device addresses a critical gap in remote cardiac monitoring, particularly for arrhythmia and impending heart attack detection, where current tools are either bulky, clinic-dependent, or lack sufficient diagnostic fidelity. Management’s commentary emphasizes that the technology enables a full range of capabilities including arrhythmia, heart attack detection, and personalized AI algorithms, all of which target large, underserved markets with established reimbursement pathways. The extended-wear patch alone targets the combined $2B long-term continuous monitor and mobile cardiac telemetry (MCT) markets, suggesting that even modest penetration could yield meaningful revenue. This multi-indication, platform-based approach transforms HeartBeam from a single-product vendor into a cardiac intelligence provider with recurring revenue potential, a narrative that remains underpriced in the current valuation.
HeartBeam’s path to profitability remains obscured by persistently rising operating expenses and a lack of meaningful revenue generation, a risk the market may be ignoring despite recent financing inflows. Research and development expenses increased to $13.5 million for the full year 2025 from $11.1 million in 2024, driven by ongoing development of the extended-wear patch, heart attack detection algorithms, and AI initiatives—yet the company reported zero product revenue in its latest financials. While management highlights progress in commercialization readiness, the absence of any disclosed sales, recurring revenue, or customer uptake metrics raises concerns about commercial execution risk. The net loss widened to $21.0 million in 2025 from $19.4 million in 2024, and although operating cash burn improved slightly due to financing inflows, the core business continues to consume capital without offsetting inflow. Until HeartBeam demonstrates scalable, recurring revenue from its FDA-cleared arrhythmia assessment system or secures reimbursement for novel indications like heart attack detection, the company remains dependent on periodic equity raises, creating dilution risk and limiting long-term shareholder value creation.
The extended-wear patch and heart attack detection initiatives—frequently cited as future growth drivers—remain in prototype or clinical validation stages with no clear timeline for FDA clearance or commercial launch, representing a significant execution risk that optimistic narratives overlook. While the JACC: Advances study provides promising proof-of-concept data for heart attack risk prediction using the HeartBeam device combined with clinical factors, it explicitly notes that the algorithm is not FDA cleared and not available in any geography. Similarly, the extended-wear patch is described as a “working prototype” showcased at investor conferences, with no indication of pivotal trial initiation or regulatory engagement. Relying on these unproven extensions to justify current valuations assumes successful navigation of complex regulatory pathways, clinical adoption, and reimbursement approval—all of which are uncertain and capital-intensive. Given that the company’s sole FDA clearance to date is for arrhythmia assessment via the credit card-sized device, overemphasizing future indications risks conflating scientific progress with near-term monetizable value.
HeartBeam operates in a highly competitive and rapidly evolving cardiac monitoring landscape where established players and well-funded startups are aggressively investing in AI-ECG and remote monitoring technologies, a competitive threat the company’s disclosures do not adequately address. The collaboration with Mount Sinai, while scientifically promising, does not preclude larger entities—such as Apple, Philips, or GE Healthcare—from developing comparable or superior AI algorithms using alternative data sources or leveraging far greater scale in clinical validation and distribution. Furthermore, the preventive cardiology and concierge care channels targeted via ClearCardio™ represent niche, high-touch markets that may limit total addressable market (TAM) expansion if HeartBeam fails to penetrate broader primary care or hospital systems. Without clear evidence of defensible intellectual property beyond its core 3D ECG synthesis patents—or demonstrable advantages in algorithmic accuracy, cost, or usability over alternatives—the company risks commoditization or being outpaced by competitors with stronger commercial infrastructure, reimbursement relationships, and brand recognition in cardiac care.
HeartBeam’s path to profitability remains obscured by persistently rising operating expenses and a lack of meaningful revenue generation, a risk the market may be ignoring despite recent financing inflows. Research and development expenses increased to $13.5 million for the full year 2025 from $11.1 million in 2024, driven by ongoing development of the extended-wear patch, heart attack detection algorithms, and AI initiatives—yet the company reported zero product revenue in its latest financials. While management highlights progress in commercialization readiness, the absence of any disclosed sales, recurring revenue, or customer uptake metrics raises concerns about commercial execution risk. The net loss widened to $21.0 million in 2025 from $19.4 million in 2024, and although operating cash burn improved slightly due to financing inflows, the core business continues to consume capital without offsetting inflow. Until HeartBeam demonstrates scalable, recurring revenue from its FDA-cleared arrhythmia assessment system or secures reimbursement for novel indications like heart attack detection, the company remains dependent on periodic equity raises, creating dilution risk and limiting long-term shareholder value creation.
The extended-wear patch and heart attack detection initiatives—frequently cited as future growth drivers—remain in prototype or clinical validation stages with no clear timeline for FDA clearance or commercial launch, representing a significant execution risk that optimistic narratives overlook. While the JACC: Advances study provides promising proof-of-concept data for heart attack risk prediction using the HeartBeam device combined with clinical factors, it explicitly notes that the algorithm is not FDA cleared and not available in any geography. Similarly, the extended-wear patch is described as a “working prototype” showcased at investor conferences, with no indication of pivotal trial initiation or regulatory engagement. Relying on these unproven extensions to justify current valuations assumes successful navigation of complex regulatory pathways, clinical adoption, and reimbursement approval—all of which are uncertain and capital-intensive. Given that the company’s sole FDA clearance to date is for arrhythmia assessment via the credit card-sized device, overemphasizing future indications risks conflating scientific progress with near-term monetizable value.
HeartBeam operates in a highly competitive and rapidly evolving cardiac monitoring landscape where established players and well-funded startups are aggressively investing in AI-ECG and remote monitoring technologies, a competitive threat the company’s disclosures do not adequately address. The collaboration with Mount Sinai, while scientifically promising, does not preclude larger entities—such as Apple, Philips, or GE Healthcare—from developing comparable or superior AI algorithms using alternative data sources or leveraging far greater scale in clinical validation and distribution. Furthermore, the preventive cardiology and concierge care channels targeted via ClearCardio™ represent niche, high-touch markets that may limit total addressable market (TAM) expansion if HeartBeam fails to penetrate broader primary care or hospital systems. Without clear evidence of defensible intellectual property beyond its core 3D ECG synthesis patents—or demonstrable advantages in algorithmic accuracy, cost, or usability over alternatives—the company risks commoditization or being outpaced by competitors with stronger commercial infrastructure, reimbursement relationships, and brand recognition in cardiac care.